UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ⊠	
Filed by a party other than the Registrant \Box	
Check the appropriate box:	
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
\boxtimes	Definitive Additional Materials
	Soliciting Material under §240.14a-12
	SECOND SIGHT MEDICAL PRODUCTS, INC. (Name of Registrant as Specified In Its Charter)
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):	
\boxtimes	No fee required.
	Fee paid previously with preliminary materials.
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.





Your Vote is Important! VOTE TODAY!

Second Sight Medical Products (Nasdaq: EYES) needs you to support its proposed merger with Nano Precision Medical.

The Board of Directors recommends you vote "FOR" on proposals 1 - 7 on your proxy, which will enable us to move forward with the merger, setting the stage for potentially creating significant shareholder value. Advantages of the merger include:

- Merger combines two operating companies developing medical implants targeting conditions with high unmet need;
- Experienced leadership team with history of successfully bringing drugs, medical devices, and drug/device combination products to commercialization;
- Combined product pipeline addresses a more than \$50 billion market opportunity.

Every vote is needed for Second Sight holders to reap the benefits of the merger. Vote today using the enclosed Voting Instruction Form.

Your Vote is Critical No Matter How Many or How Few Shares You Own.

Please vote today. Voting is quick and easy. You can vote by INTERNET, TELEPHONE, or MAIL.

Please refer to the enclosed Voting instruction form.

If you have any questions or need any assistance to vote your shares please contact Morrow Sodali, LLC: Toll Free (US & Canada): (800) 662-5200 International: (203) 658-9400 Email: EYES@info.morrowsodali.com

Safe Harbor

This solicitation material may contain certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would, "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made herein regarding the proposed merger, including the benefits of the proposed business combination, integration plans, expected synergies and opportunities, the expected management and governance of the combined company, and the expected timing of the proposed transactions contemplated by the definitive merger agreement. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Second Sight's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or could otherwise cause the merger transaction to fail to colose; (2) the outcome of any legal proceedings that may be instituted against Second Sight to TMP following announcement of the Merger, (3) the inability to complete the Merger, including due to failure to obtain approval of the shareholders of Second Sight or NDM following announcement and